Home Federal Bank of Tennessee Reduces Stake in Eli Lilly and Company (NYSE:LLY)

Home Federal Bank of Tennessee reduced its holdings in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 1.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,936 shares of the company’s stock after selling 225 shares during the period. Eli Lilly and comprises 2.1% of Home Federal Bank of Tennessee’s portfolio, making the stock its 4th largest holding. Home Federal Bank of Tennessee’s holdings in Eli Lilly and were worth $5,491,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of LLY. Vanguard Group Inc. grew its position in Eli Lilly and by 1.8% in the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after acquiring an additional 1,219,424 shares in the last quarter. State Street Corp raised its stake in shares of Eli Lilly and by 2.5% during the fourth quarter. State Street Corp now owns 33,929,864 shares of the company’s stock valued at $9,372,107,000 after acquiring an additional 813,983 shares in the last quarter. Capital World Investors raised its stake in Eli Lilly and by 17.0% in the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after buying an additional 3,242,548 shares in the last quarter. Capital International Investors grew its holdings in Eli Lilly and by 30.5% in the first quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after purchasing an additional 2,063,557 shares during the last quarter. Finally, Norges Bank purchased a new position in Eli Lilly and in the fourth quarter worth $2,213,765,000. 82.45% of the stock is owned by institutional investors.

Eli Lilly and Stock Performance

Shares of Eli Lilly and stock traded up $0.39 during midday trading on Friday, hitting $311.26. The company had a trading volume of 134,176 shares, compared to its average volume of 2,237,822. The stock has a market cap of $295.75 billion, a PE ratio of 49.58, a P/E/G ratio of 1.92 and a beta of 0.38. Eli Lilly and Company has a 1-year low of $220.20 and a 1-year high of $335.33. The business’s 50 day simple moving average is $314.33 and its two-hundred day simple moving average is $304.45. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion during the quarter, compared to the consensus estimate of $6.85 billion. During the same period in the prior year, the firm earned $1.87 earnings per share. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. As a group, equities analysts predict that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were given a dividend of $0.98 per share. The ex-dividend date was Friday, August 12th. This represents a $3.92 annualized dividend and a dividend yield of 1.26%. Eli Lilly and’s payout ratio is currently 62.52%.

Wall Street Analyst Weigh In

Several research firms have commented on LLY. Barclays upped their price target on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, July 7th. Morgan Stanley increased their price objective on shares of Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 7th. BMO Capital Markets increased their target price on shares of Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a report on Tuesday, September 6th. UBS Group upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $335.00 to $363.00 in a research note on Thursday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $332.19.

Insider Activity at Eli Lilly and

In other Eli Lilly and news, Director Jackson P. Tai acquired 656 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The stock was acquired at an average cost of $304.19 per share, for a total transaction of $199,548.64. Following the transaction, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Jackson P. Tai acquired 656 shares of the company’s stock in a transaction dated Friday, August 12th. The shares were bought at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the purchase, the director now directly owns 62,857 shares in the company, valued at approximately $19,120,470.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 177,243 shares of the business’s stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $330.28, for a total value of $58,539,818.04. Following the transaction, the insider now directly owns 103,983,810 shares in the company, valued at $34,343,772,766.80. The disclosure for this sale can be found here. In the last three months, insiders sold 328,125 shares of company stock worth $108,581,151. 0.12% of the stock is owned by company insiders.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.